Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00892567 · ClinicalTrials.gov registry record · Phase 1
Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer
A Phase 1 study of Breast Neoplasms, sponsored by Craig L Slingluff, Jr.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00892567 is a Phase 1 study of Breast Neoplasms that has completed, run by Craig L Slingluff, Jr. The registered enrollment target is 9 participants, below the 569-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00892567, a Phase 1 study of Breast Neoplasms, has completed, sponsored by Craig L Slingluff, Jr.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate T cell responses against a peptide-based vaccine in patients with breast cancer and to determine whether peptide-specific T cells can be found at the site of breast tumors following vaccination.
Conditions Studied
Interventions
- BIOLOGICAL 9 Peptides from Her-2/neu, CEA, & CTA
Study Locations (1)
Virginia
- University of Virginia Health System - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00892567
The ClinicalTrials.gov registry entry for NCT00892567 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 569-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (98% lower). The listed sponsor is Craig L Slingluff, Jr, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which 9 Peptides from Her-2/neu, CEA, & CTA is the first listed.
NCT00892567 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT00892567 about?
NCT00892567 is a clinical study titled "Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer". The purpose of this study is to evaluate T cell responses against a peptide-based vaccine in patients with breast cancer and to determine whether peptide-specific T cells can be found at the site of breast tumors following vaccination.
What is the current status of trial NCT00892567?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2009-05. Estimated completion is 2012-02.
What conditions does trial NCT00892567 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT00892567?
The interventions under investigation include: 9 Peptides from Her-2/neu, CEA, & CTA (BIOLOGICAL).
Who is sponsoring clinical trial NCT00892567?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00892567 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RECRUITING · Phase 1
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RECRUITING · Phase 1
-
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
RECRUITING · Phase 1
-
A Study of DM001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.